Table 1.
Outcomes in RCD by country
| Author | Country | RCD patients (N) | Evolution into EATL | Mortality | 5-year survival rate |
| Malamut G, Gastroenterology 200944 | France | Total=57 RCD1=14 RCD2=43 |
Total=18 (32%) RCD1=2 (14%) RCD2=16 (37%) |
Total=29 (51%) RCD1=3 (21%) RCD2=26 (60%) |
RCD1=93% RCD2=44% |
| Al-Toma A, Gut
200749 |
The Netherlands | Total=93 RCD1=43 RCD2=50 |
Total=26 (28%) RCD1=0 RCD2=26 (52%) |
Total=54 (58%) RCD1=3 (7%) RCD2=28 (56%) RCD2 +EATL=23 (88%) |
RCD1=96% RCD2=58% RCD2 +EATL=8% |
| Rubio-Tapia A, Gastroenterology
200943 |
USA | Total=57 RCD1=42 RCD2=15 |
Total=10 RCD1=0 RCD2=10 (67%) |
Total=15 (26%) RCD1=8 (19%) RCD2=7 (46%) |
RCD1=80% RCD2=45% |
| Daum S, Eur J Gastr Hepatol
200950 |
Germany | Total=32 RCD1=23 RCD2=9 |
Total=4 (12%) RCD1=0 RCD2=4 (44%) |
Total=8 (25%) RCD1=4 (17%) RCD2=4 (44%) |
RCD1=90% RCD2=53% |
| Roshan B, Am J Gastroenterol
201145 |
USA | Total=29 RCD1=24 RCD2=5 |
Total=2 RCD1=0 RCD2=2 |
Total=2 (EATL) RCD1=0 RCD2=2 |
RCD1=100%* RCD2=60%* (*2-year mortality) |
| Nasr I, Nutrients
2015*73 |
UK | Total=30 RCD1=0 RCD2=30 |
None | None | All alive |
*The only previous UK study assessing RCD2 reported a 5-year survival of 100%73; however, the diagnosis of RCD2 was made solely on TCR clonality which is unreliable. Given the disparity of outcome in this UK study, and by comparison to the international literature, it is likely that the patients in this cohort may have been predominantly RCD1.
EATL, enteropathy-associated T-cell lymphoma; RCD, refractory coeliac disease.